Author Archives: Marta Figueiredo PhD

Study to Test If Wearable Device Can Predict Symptom Worsening

Researchers at the University of Alberta are studying whether combining a commercially available wearable device with artificial intelligence can effectively predict symptom worsening in people with chronic lung conditions, such as idiopathic pulmonary fibrosis (IPF). Developed by New York-based Health Care Originals to monitor asthma, the ADAMM-RSM…

Tyvaso Improved Lung Function in IPF Patients With PH

Four months of treatment with Tyvaso (inhaled treprostinil) significantly improved lung function in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD), according to a post-hoc analysis of data from the Phase 2/3 INCREASE clinical trial. PH-ILD comprises a group of conditions characterized by significant lung scarring (fibrosis), including…

Inhaled PRS-220 Aims to Treat Both IPF and ‘Long Covid’ PF

Pieris Pharmaceuticals plans to start clinical development of PRS-220 in 2022 for idiopathic pulmonary fibrosis (IPF) — and also will advance the investigative, inhaled therapy for “long COVID” PF, or post-COVID-19 pulmonary fibrosis, the company said. The clinical development of PRS-220 for long COVID pulmonary fibrosis will be…

Work Stops on Fezagepras, or PBI-4050, as Potential IPF Treatment

Liminal BioSciences is stopping the clinical development of its investigative oral therapy fezagepras (PBI-4050) for idiopathic pulmonary fibrosis (IPF), based on interim pharmacological data from a Phase 1 clinical trial testing it at ascending doses in healthy volunteers. The decision comes less than a month after the company announced plans…

Changes in Blood Cell Ratios Linked to Worse Outcomes

Idiopathic pulmonary fibrosis (IPF) patients showing greater changes in blood cell ratios often used as markers of inflammation are at higher risk of lung function decline, respiratory hospitalization, and death, according to a post-hoc analysis of data from several Phase 3 clinical trials. Notably, these associations were more pronounced…

Galapagos Advances GLPG4617 Into Phase 2 Trial

In a move that refocuses its clinical pipeline, Galapagos is discontinuing the development of GLPG1205, its experimental therapy for idiopathic pulmonary fibrosis (IPF), and advancing its most recent IPF candidate, GLPG4617, into a Phase 2 clinical trial. These and other decisions toward a “more risk-balanced pipeline” are…